Celiac Disease Jeffrey Fine, MD. Celiac disease ) Autoimmune disorder with a prevalence of approximately 0.5 to 1 percent in the United States. (1 in.

Slides:



Advertisements
Similar presentations
Celiac Disease SYED A. SADIQ, MD GASTROENTEROLOGY ASSOCIATE OF NORTH TEXAS
Advertisements

The “Great Mimic” Disease
A.M. Report 5/5/09 Jason Haag, M.D.
Definition. Celiac disease is an immune-mediated enteropathycaused by a permanent sensitivity to gluten in genetically susceptible individuals. It occurs.
Celiac disease Prepared by :Maha Hmeidan nahal.
THE CELIAC PATIENT Carol E. Semrad, M.D. Associate Professor of Medicine The University of Chicago.
Dr Nader Ghaderi, GPR. General information First described in ancient Greek by Aretaeus of Cappadocia The word Coeliac was first used in 19 th century.
The prospective study and the new ESPGHAN protocol L. Greco, D. Mičetić-Turk Mediterranean Network for Celiac Disease Istanbul, June 30th 2012.
Gastrointestinal Block Pathology lecture Nov 25, 2012 Dr. Maha Arafah Dr. Ahmed Al Humaidi Malabsorption.
CELIAC DISEASE Done by Fifunmi Laosebikan Samanth Datta Charles Merigini Tamosa aka Boss King.
Celiac Disease and Gluten Sensitivity A Case-based Approach to Gastroenterology Kimberly Carter, MS, PA-C Division of Gastroenterology University of Pennsylvania.
Coeliac Disease Eileen Parrott. Very common. We all miss opportunities to diagnose. At least 1% of population. Runs in families. Peak incidence currently.
SCREENING FOR CELIAC DISEASE IN EGYPTIAN CHILDREN SCREENING FOR CELIAC DISEASE IN EGYPTIAN CHILDREN Prof. Dr: Mona Abu Zekry -Professor of Pediatrics Head.
Celiac Disease in Children Dascha C. Weir, MD Boston Children’s Hospital Harvard Medical School Gluten Free for Life Conference April 11, 2015.
Clinical Presentation of Celiac Disease Alessio Fasano, M.D. Mucosal Immunology and Biology Research Center And Center for Celiac Research – Celiac Program.
Can genotyping help to diagnose coeliac disease?
Celiac Disease Ryan Sanford 3/30/10.
HPI 35 year old caucasian female presents to your clinic with 3 month history of diarrhea, bloating, and fatigue. What else would you like to know?
 An autoimmune disease where the protein gluten damages the villi in the small intestine causing malabsorption.  Celiac Disease is a lifelong condition.
Celiac Disease in Primary Care Dustin M Adkins Spring 2007.
Eat to Heal... the Cure is Food!. Overview  Celiac Disease Definition Symptoms and presentations Diagnosis Treatment  The Kogan Celiac Center at Barnabas.
MALABSORPTION SYNDROME
Lower Gastrointestinal Tract KNH 411. © 2007 Thomson - Wadsworth.
Dr. Adnan Hamawandi Professor of Pediatrics
Celiac Disease and tropical sprue
Presentation by Margaret Roberts.  First described in 1880  Link to diet was not described until 1950  In 1954, Dr. Paulley showed that intestinal.
Coeliac Disease Jaide Brown Breea Buckley Krissy Rowe.
Lower Gastrointestinal Tract KNH 411. © 2007 Thomson - Wadsworth.
Gluten Free Diet Accommodating the Gluten Free Diet in The PCH Setting.
Celiac Disease Provided Courtesy of Nutrition411.com Review Date 11/14 G-0605.
Copyright HD Scientific All Rights Reserved 1 When Is Intestinal Gas Dangerous? Dangerous?
Failure to Thrive in Toddler By: Celeste Schwartz, Melissa Rivera, Emily Foley, Yazmin Irazoqui-Ruiz.
Coeliac Disease INSERT PRESENTERS NAME. What is Coeliac disease? Coeliac disease affects approximately 1 in 100 Australians. However 75% currently remain.
Raneen Omary. Contents Definition Pathogenesis Epidemiology Acute Radiation Enteritis Chronic Radiation Enteritis Risk Factors Diagnosis DD Medical Management.
Malabsorption 9/14/ CONDITIONS OF MALABSORPTION Malabsorption: is the inability of the digestive system to absorb one or more of The major vitamins(
Coeliac disease NICE Clinical Guideline 86, May 2009.
A B Fasting improve the condition inflammatory bowel diseases
THE IMPORTANCE OF DIAGNOSIS AND DIET THERAPY IN CELIAC DISEASE Author: Miklos Andreea Doriana Coordinator: Lecturer dr. Fárr Ana-Maria.
Ben Greenfield 28 September Epidemiology 1% of the population in North America More common in the Caucasian population, very rare in Asian and African.
Celiac Disease.
JOHN ZUBIALDE, MD PROFESSOR OF FAMILY AND PREVENTIVE MEDICINE UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE Celiac Disease: Myths and Reality.
1 Celiac Disease Chloe Bierbower Kelly Lonergan Brittany Pinkos Sarah Steinmetz.
Celiac Disease.
CELIAC DISEASE. ESPGHAN 2012 : Guidelines for the Diagnosis in Children & Adolescents Definition: “CD is an immune-mediated systemic disorder elicited.
JESSIE BUTTS AMANDA SCHUESSLER Celiac Disease. What is Celiac Disease? Genetically based autoimmune disease  Of all 8 0, only one with a known trigger.
Primary Care Approach to Celiac Disease
CELIAC DISEASE BY EMER BYRNE
Coeliac Disease (CD) By Dr. Zahoor.
The First MEDICEL Meeting Cairo 30 th April to 1 st May 30 th April to 1 st May Prof. Luigi Greco Dr. Laura Timpone Following ESPGHAN PROTOCOL REVISION.
SERUM CYTOKINE PATTERNS IN CELIAC DISEASE Shabab Naqvi & Ibrahim Ibrahim Mentor: Dr. Sanil Manavalan Columbia University, College of Physicians and Surgeons.
Celiac Disease Gluten Sensitive Enteropathy. Celiac Disease: Immune mediated enteropathy caused by permanent sensitivity to gluten in genetically susceptible.
Coeliac Disease. What is Coeliac disease? Autoimmune Heightened immunological response to ingested GLUTEN In genetically susceptible people.
Disorders of Malabsorption. Malabsorption It is a descriptive term of many diseases and is not a diagnosis It is a descriptive term of many diseases and.
1 Celiac’s Disease Chloe Bierbower Kelly Lonergon Brittany Pinkos Sarah Steinmetz.
ESPGHAN COMMITTEE to revise the diagnostic protocol of Celiac Disease Prof. Riccardo Troncone, President March 2010.
Celiac Sprue Common cause of malabsorption of one or more nutrients in Caucasians, especially those of European descent Also known as non-tropical sprue,
Diagnosis and Treatment of Celiac Disease in Children
Celiac Disease Equipping primary care physicians to manage most patients Eric Poulin, MD First Light Health System Mora, Minnesota.
Celiac Disease Ben Thomas, D.O. Gastroenterology Specialty Medicine Care, Beavercreek, OH.
Celiac Disease Histopathology - prior to Tx Flat biopsy with surface damage Increased Intraepithelial lymphocytes Increased lamina propria inflammation.
Presented by: Dallas Montag Date: 12/6/16
Celiac Disease and Autoimmune Diseases
Compliant with neg bx (6) Compliant with pos bx (3)
Gastroenterology: Celiac Disease
Celiac Disease By: Michele Arave CNA certified Diagnosed with Celiac.
Coeliac Disease at ABCD
Malabsorption syndrome
Small intestinal disorders
Pathology and mechanisms of malabsorption
Celiac Disease in women
Presentation transcript:

Celiac Disease Jeffrey Fine, MD

Celiac disease ) Autoimmune disorder with a prevalence of approximately 0.5 to 1 percent in the United States. (1 in every persons) Inappropriate immune response to the dietary protein gluten, which is found in rye, wheat, and barley. After absorption in the small intestine these proteins interact with the antigen-presenting cells in the lamina propria causing an inflammatory reaction that targets the mucosa of the small intestine in genetically sensitive people. Manifestations range from no symptoms to overt malabsorption with involvement of multiple organ systems and an increased risk of some malignancies.

Genetics Most all patients with celiac disease express human leukocyte antigen (HLA)-DQ2 or HLA-DQ8, which facilitate the immune response against gluten protein Concordance rates of 70 to 75 % among monozygotic twins and 5 to 22 % among first-degree relatives. Genome wide associations (GWAS) identified -8 new genes,7/8 contained immune related genes and 4/8 loci share other autoimmune /inflammatory disorders –one of SNP associated w/ Crohn’s

Diagnosis Classic Celiac Disease –occurs 5% -easy to make Atypical -Difficult to make The Great Masquerader

Phenotype Grade 1 Typical symptoms Grade 2 Mild symptoms Grade 3 Asymptomatic T -lymphocyte associated protein cytotoxic T-lymphocyte antigen 4 Polymorphism (CTLA-4+49 A/G) genotype on Chromosome 2 q33

Epigenic Factors Adenovirus/Enteric Infections Stressors Surgery

Risk Factors for Celiac Disease Prevalence among Dermatitis herpetiformis 100 First-degree relative with5 to 22 celiac disease Autoimmune thyroid disease 1.5 to 14 Down syndrome5 to 12 Turner's syndrome2 to 10 Type 1 diabetes mellitus 10 Children3 to 8 Adults2 to 5

Dermatitis Herpetiformis

Signs and Symptoms Classic Diarrhea Fatigue Borborygmus Abdominal pain Weight loss Abdominal distention Flatulence Atypical Osteopenia/ osteoporosis Abnormal liver function Vomiting Folate /Iron-deficiency anemia Neurologic dysfunction Brain Fog/ dementia Constipation Nausea Esophageal reflux Up to 38 % Asymptomatic

Test selectively as part of the medical evaluation when symptoms could be secondary to celiac disease: Autoimmune thyroid disease Cerebellar ataxia First- or second-degree relative with celiac disease Irritable bowel syndrome Peripheral neuropathy Recurrent migraine Refractory Crohn’s Disease Psoriasis Selective immunoglobulin A deficiency Short stature (in children) Sjögren's syndrome Turner's syndrome Type 1 diabetes mellitus Unexplained delayed puberty Unexplained recurrent fetal loss/Infertility Seizures

SEROLOGY Serum IGA and IgA tissue transglutaminase (tTG) antibodies. Sensitivity and specificity > 95%. Do Deaminated Antigliadin antibodies DE –AGA IgG And IgA and do TTG IGG as well. Testing for gliadin antibodies is no longer recommended because of the low sensitivity and specificity for celiac disease, but should be considered for gluten sensitivity. TTG is less costly because it uses an enzyme-linked immunosorbent assay; When the prevalence is low, as in the general U.S. population, the risk of a false-positive result is high Confirmatory testing, including small bowel biopsy, is advised.

TESTING Serologic Testing Stool Testing Genetic HLA Testing Endoscopy, Pill Endoscopy and SB series

SMALL BOWEL BIOPSY Required to confirm the diagnosis of celiac disease for most patients. Should be considered in patients with negative serologic test results who are at high risk or in whom the physician strongly suspects celiac disease. Mucosal changes may vary from partial to total villous atrophy, or may be characterized by subtle crypt lengthening or increased epithelial lymphocytes. To avoid false-negative results on endoscopic biopsy, most authorities recommend obtaining at least four tissue samples, which increases the sensitivity of the test.

ENDOSCOPIC FINDING Scalloped folds Decrease in Kerckring folds Mucosal fissuring Flattened folds Normal appearing

Normal small intestine Celiac DiseaseVillous atrophy Normal villi

BENIGN COMPLICATIONS Small bowel adenomatous polyps Identified on sbft, vce or enteroscopy

MALIGNANT COMPLICATIONS Enteropathy –type Intestinal T cell Lymphoma x ^ if GFD, 70x if not Other Lymphomas 23x Small Bowel Adenocarcinomas -80x Head and Neck cancer-23x Esophageal Squamous Cell cancers 23x Other cancers ^ risk

TREATMENT Avoidance of food products that contain gluten proteins. It is essential that the diagnosis be confirmed before submitting patients to this therapy. Key elements to successful treatment include the motivation of the patient, the attentiveness of the physician to comorbidities that need to be addressed. Formal consultation with a trained dietitian is necessary. The dietitian plays a vital role in helping the patient successfully adapt to the necessary behavioral changes and may provide much of the required follow-up. National celiac disease support organizations can provide patients invaluable resources for information and support.

COMORBIDITIES Thyroid dysfunction Deficiencies in folic acid, vitamin B12, fat-soluble vitamins, calcium, magnesium, copper,zinc and iron Osteoporosis Increased mortality due to increased risk of malignancy Non-Hodgkin's lymphoma (3-6x more likely) Oropharyngeal, esophageal, and small intestinal adenocarcinoma.

Vitamin and Mineral Deficiencies Vitamin D and other Fat soluble Vitamins Folate and B12 Calcium, Magnesium, Copper and Zinc

Follow-up. Antibody levels return to normal within 12 months of starting a gluten-free diet. A repeat small bowel biopsy three to four months after initiation of a gluten-free diet is not necessary if the patient responds appropriately to therapy. If the patient does not respond as expected despite adherence to a gluten-free diet, the physician should consider diseases that may mimic celiac disease vs refractory sprue

Screening. Screening an asymptomatic patient for celiac disease must be weighed against the psychological, emotional, and economic impact of a false positive result Also, it would necessitate further evaluation with small bowel biopsy. The need to follow a strict diet indefinitely can adversely affect the patient's perceived quality of life. Routine screening of the general population is not recommended. But should be considered Persons at high risk for celiac disease who exhibit any level of symptoms, appropriate testing is indicated.

Special Topics FERTILITY PROBIOTICS NON IMMUNE GLUTEN SENSITIVITY REFRACTORY SPRUE MY PARADIGM NEW TESTING POTENTIAL THERAPIES

Fertility in Celiac Disease Delayed menses/ Premature Menopause Amenorrhea Recurrent abortions Relative Infertility Women and Men Low birth weight babies Increased Perinatal Mortality Poor Outcomes of Fertility may be corrected GFD – minimum 6-9 mos

Probiotics Good bacteria such as lactobacillus and bifidiobacterium decrease on gluten free diet Pathogenic bacteria proliferated RX : probiotic should be taken-lactobacillus and bifidiobacterium 10 billion CFUS to start daily

Differential Diagnosis of Celiac Disease Anorexia nervosa Autoimmune enteropathy Bacterial overgrowth Collagenous sprue Crohn's disease- co-exist Giardiasis Human immunodeficiency virus enteropathy Hypogammaglobulinemia Infective gastroenteritis Intestinal lymphoma Irritable bowel syndrome Ischemic enteritis Lactose intolerance Pancreatic insufficiency Soy protein intolerance Tropical sprue Tuberculosis Whipple's disease Zollinger-Ellison syndrome

Non Immune Gluten Sensitivity This is Real ! Antigenic nature of gliadin Zonulin –protein suggested to increase intestinal permeability- “Leaky Gut” DQ1 alleles are GS genes subtype DQ5, 6 DQ2subtype DQ2, DQ3 st7,8,9 As are Celiac Genes

Refractory Celiac Disease RCD 1-IELS w/ polyclonal and have nl Phenotype RCD 2 abberant IELS and monoclonality 50% Develop Enteropathy Associated Lymphoma

CELIAC DISEASE IgA and IGG tissue transglutaminase and,DeAGA antibodies, IgA and IGG levels and IgA and IGG endomysial antibodies are appropriate first-line serologic tests to rule in celiac disease. If negative I do enterolab’s stool for AGA if positive I do HLA testing, small bowel biopsy and a pill cam IF I BELIEVE THEY HAVE CELIAC DISEASE- Check labs for CBC, CMP,25 D b12,, TSH, Minerals and vitamin testing, Bone Dexa and follow lifelong

New Testing on Horizon Not clinically available Measuring –serum levels of Th-2 Cytokines IL-4 and 10 and inflammatory cytokines IL-1a,1B and 8- correlates w/ IGA –TTG titres Galectin -10 –lysophospholipase in WBC associated in gut epithelium correlates w/ Histology T -lymphocyte associated protein cytotoxic T-lymphocyte antigen 4 Polymorphism sCTLA-4-gene higher in celiac disease and other auto immune disease

Potential Therapies Breast feed, delay/decrease infant gluten exposure Farrell RJ, JAMA 2005 Predigest Gluten Molecules – endopetidases Genetic Modified Wheat Strains – for better? Inhibit Zonulin - AT larazotide- in Phase 2 trials Immunotherapy Anti-interferon-gamma and TNF alpha

Potential Therapies Anti-TTG blockers Anti-HLA DR2/DR8

Questions

Reference Presutti J,Cangemi J, Cassidy H, Hill D, Celiac Disease. American Family Physician. December 15, 2007: Enterolab website and HLA info from Gluten Seminar Fasano, A,Zonulin Physiol Rev 91, ,2011 Tennyson C, Lewis S and Green P, New and Developing Therapies for Celiac disease, Therap Adv Gastroenterol Sept 2(5): Advances in Celiac Disease 2011, Curr Opin Gastroenterol. 2011;27(2): © 2011 Lippincott Williams & Wilkins

References Advances in Coelic Disease, Alimentary Pharmacology & Therapeutics. 2012;35(7): © 2012 Blackwell Publishing

Break